[1] S PATEL. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity.[J]. Molecular Pharmacology, 1997, 52 4: 658-666. DOI:
10.1124/mol.52.4.658[2] R J BOUCEK. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.[J]. The Journal of Biological Chemistry, 1987, 262 33: 15851-15856.
[3] EMANUELA SALVATORELLI. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 318 1: 424-433. DOI:
10.1124/jpet.106.103846[4] ALVARO MORDENTE . Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications[J]. Biochemical pharmacology, 2003, 66 6: Pages 989-998. DOI:
10.1016/s0006-2952(03)00442-8
